Plaque reduction neutralization test for measles antibodies: Description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination
- PMID: 18063236
- DOI: 10.1016/j.vaccine.2007.10.046
Plaque reduction neutralization test for measles antibodies: Description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination
Abstract
Background: Clinical trials of measles vaccination administered as aerosol are planned with the aim of obtaining licensure. Measles antibody levels will be measured using the plaque reduction neutralization test (PRNT) to assess antibody responses as a surrogate marker of efficacy.
Methods: A working group examined laboratory protocols for measles PRNT in use at three reference centres and agreed to a standardised procedure, which was subsequently validated.
Results: Assay validation showed quantitative results varied approximately threefold both within and between assays. The lower limit of detection was approximately 20milliInternational Units/mL.
Conclusions: A standardised laboratory protocol for measles PRNT was established and validated for use in clinical trials of aerosolized measles vaccines.
Similar articles
-
Comparison of plaque reduction neutralisation test (PRNT) and measles virus-specific IgG ELISA for assessing immunogenicity of measles vaccination.Vaccine. 2008 Nov 25;26(50):6392-7. doi: 10.1016/j.vaccine.2008.08.074. Epub 2008 Oct 1. Vaccine. 2008. PMID: 18834911
-
Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: randomized trials in Mexican schoolchildren.Bull World Health Organ. 2002;80(10):806-12. Epub 2002 Nov 28. Bull World Health Organ. 2002. PMID: 12471401 Free PMC article. Clinical Trial.
-
Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children.Vaccine. 2006 Jan 30;24(5):683-90. doi: 10.1016/j.vaccine.2005.08.045. Epub 2005 Aug 24. Vaccine. 2006. PMID: 16154241
-
Evaluation of a measles vaccine campaign in Ethiopia using oral-fluid antibody surveys.Vaccine. 2008 Sep 2;26(37):4769-74. doi: 10.1016/j.vaccine.2008.07.005. Epub 2008 Jul 21. Vaccine. 2008. PMID: 18644417 Review.
-
Measles vaccination: new strategies and formulations.Expert Rev Vaccines. 2008 Oct;7(8):1215-23. doi: 10.1586/14760584.7.8.1215. Expert Rev Vaccines. 2008. PMID: 18844595 Review.
Cited by
-
Comparison of measles plaque reduction neutralization test (PRNT) and measles virus-specific IgG ELISA for assessment of immunogenicity of measles-mumps-rubella vaccination at 5-7 months of age and maternal measles antibodies.Vaccine X. 2024 Aug 16;20:100548. doi: 10.1016/j.jvacx.2024.100548. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39247133 Free PMC article.
-
A Cross-Sectional Study of Measles-Specific Antibody Levels in Australian Blood Donors-Implications for Measles Post-Elimination Countries.Vaccines (Basel). 2024 Jul 22;12(7):818. doi: 10.3390/vaccines12070818. Vaccines (Basel). 2024. PMID: 39066455 Free PMC article.
-
Serosurveillance for Measles and Rubella.Vaccines (Basel). 2024 Jul 22;12(7):816. doi: 10.3390/vaccines12070816. Vaccines (Basel). 2024. PMID: 39066453 Free PMC article. Review.
-
Risk Factors for Impaired Cellular or Humoral Immunity after Three Doses of SARS-CoV-2 Vaccine in Healthy and Immunocompromised Individuals.Vaccines (Basel). 2024 Jul 8;12(7):752. doi: 10.3390/vaccines12070752. Vaccines (Basel). 2024. PMID: 39066390 Free PMC article.
-
A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial.Lancet. 2024 May 11;403(10439):1879-1892. doi: 10.1016/S0140-6736(24)00532-4. Epub 2024 Apr 29. Lancet. 2024. PMID: 38697170 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
